Barr Laboratory BRL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Silverman who wrote (81)	10/25/1997 8:54:00 AM
From: harkenman	Read Replies (2) of 207

Why <and the stock will test old highs>? Don't you think BRL has the manegement to differentiate itself from the other "me-too generics"? With this type of earnings growth rate (Cipro settlement 'till year 2004, the Warfarin launch, Estrace approval, etc.). The Estrace approval though I do not have the sales figures since it appears to be a less than $225 million/year product it does show up on my radar screen as a top 100 prescribed drug. That should add to something. What is the new PE ratio when we account for these latest figures? I'll hold on to my measly 1000 shares and only sell fractions after splits. We will see how MYL fares this Q. I think these two companies are the only serious (profitable) generic competitorS out there.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next